Benitec Biopharma this week announced that the University of California, San Diego, has been selected as another site of the company’s phase I/II trial of the expressed RNAi-based hepatitis C treatment TT-034.
Last month, the company said that the Duke Clinical Research Unit would also be a site for the trial (GSN 3/28/2013).
The trial is designed to evaluate single escalating doses of the drug in patients with chronic HCV genotype I infection who have failed previous treatment, Benitec said.
It is expected to enroll 14 patients in five sequential dose cohorts, with the possibility of additional cohorts to confirm study findings. Endpoints include safety, as well as serum viral load reduction and hepatocyte transduction levels.